Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LCTX

LCTX - Lineage Cell Therapeutics Inc Stock Price, Fair Value and News

$1.57-0.06 (-3.68%)
Market Closed

10/100

LCTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

LCTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.29

Target 3M

$1.45

Target 6M

$1.37

LCTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LCTX Price Action

Last 7 days

-5.4%

Last 30 days

-3.7%

Last 90 days

-14.7%

Trailing 12 Months

149.2%

LCTX RSI Chart

LCTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LCTX Valuation

Market Cap

361.6M

Price/Earnings (Trailing)

-5.34

Price/Sales (Trailing)

33.43

EV/EBITDA

-19.98

Price/Free Cashflow

-17.32

LCTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.29

Target 3M

$1.45

Target 6M

$1.37

LCTX Fundamentals

LCTX Revenue

Revenue (TTM)

10.8M

Rev. Growth (Yr)

-2.59%

Rev. Growth (Qtr)

33.13%

LCTX Earnings

Earnings (TTM)

-67.7M

Earnings Growth (Yr)

-881.58%

Earnings Growth (Qtr)

2.24%

LCTX Profitability

Operating Margin

97.49%

EBT Margin

-171.80%

Return on Equity

-306.97%

Return on Assets

-75.48%

Free Cashflow Yield

-5.77%

LCTX Investor Care

Shares Dilution (1Y)

21.97%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20259.6M10.9M10.8M0
20248.0M6.2M8.7M9.5M
202311.9M10.5M8.8M8.9M
20225.6M10.1M13.0M14.7M
2021666.0K684.0K751.0K445.0K
2020678.0K000
2019545.0K322.0K256.0K257.0K
20182.3M2.3M691.0K691.0K
20174.9M3.8M2.8M1.8M
20167.0M6.5M6.1M5.9M
20154.5M5.4M6.3M5.9M
20144.1M4.0M4.4M4.4M
20133.3M3.4M3.0M3.6M
20124.2M4.4M4.0M3.5M
20113.8M3.8M4.2M4.4M
201002.5M3.1M3.7M
20090001.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Lineage Cell Therapeutics Inc

LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
 CEO
 WEBSITEhttps://lineagecell.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES70

Lineage Cell Therapeutics Inc Frequently Asked Questions

LCTX is the stock ticker symbol of Lineage Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Lineage Cell Therapeutics Inc is 361.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LCTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether LCTX is over valued or under valued. Whether Lineage Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lineage Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LCTX.

As of Wed Jan 28 2026, LCTX's PE ratio (Price to Earnings) is -5.34 and Price to Sales (PS) ratio is 33.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LCTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Lineage Cell Therapeutics Inc has provided -0.042 (multiply by 100 for percentage) rate of return.